VenoStent is an advanced materials company with patented core technology in polymer engineering. Its first product, SelfWrap, is a slip-on, bioresorbable wrap aimed to eliminate vascular access surgery failure rate of 55-65% in hemodialysis patients. The extra costs to the Centers for Medicare and Medicaid Services (CMS) created by these failures amounts to over $2 billion per year.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/23/21 | $2,300,000 | Seed |
C3 Ventures Cowtown Angels Creative Ventures  IAG Capital Partners Olima Ventures SP Investment Fund Texas Halo Fund | undisclosed |
